200,000+ products from a single source!
sales@angenechem.com
102052-95-9 | 3-Cyclopentene-1,2-diol, 5-(4-amino-1H-imidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)-, (1S,2R,5R)-
CAS No: 102052-95-9 Catalog No: AG0006H5 MDL No:MFCD12545899
Product Description
Catalog Number:
AG0006H5
Chemical Name:
3-Cyclopentene-1,2-diol, 5-(4-amino-1H-imidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)-, (1S,2R,5R)-
CAS Number:
102052-95-9
Molecular Formula:
C12H14N4O3
Molecular Weight:
262.2646
MDL Number:
MFCD12545899
IUPAC Name:
(1S,2R,5R)-5-(4-aminoimidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol
InChI:
InChI=1S/C12H14N4O3/c13-12-9-7(1-2-14-12)16(5-15-9)8-3-6(4-17)10(18)11(8)19/h1-3,5,8,10-11,17-19H,4H2,(H2,13,14)/t8-,10-,11+/m1/s1
InChI Key:
OMKHWTRUYNAGFG-IEBDPFPHSA-N
SMILES:
Nc1nccc2c1ncn2[C@@H]1C=C([C@H]([C@H]1O)O)CO
UNII:
544SH4020S
Properties
Complexity:
378
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
3
Defined Bond Stereocenter Count:
0
Exact Mass:
262.107g/mol
Formal Charge:
0
Heavy Atom Count:
19
Hydrogen Bond Acceptor Count:
6
Hydrogen Bond Donor Count:
4
Isotope Atom Count:
0
Molecular Weight:
262.269g/mol
Monoisotopic Mass:
262.107g/mol
Rotatable Bond Count:
2
Topological Polar Surface Area:
117A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
-1.7
Literature
| Title | Journal |
|---|---|
| Upregulation of histone-lysine methyltransferases plays a causal role in hexavalent chromium-induced cancer stem cell-like property and cell transformation. | Toxicology and applied pharmacology 20180301 |
| Resveratrol suppresses myofibroblast activity of human buccal mucosal fibroblasts through the epigenetic inhibition of ZEB1 expression. | Oncotarget 20160315 |
| Epigenetic silencing of microRNA-218 via EZH2-mediated H3K27 trimethylation is involved in malignant transformation of HBE cells induced by cigarette smoke extract. | Archives of toxicology 20160201 |
| Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. | Leukemia 20131201 |
| Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. | Lung cancer (Amsterdam, Netherlands) 20121101 |
| Targeting the enhancer of zeste homologue 2 in medulloblastoma. | International journal of cancer 20121015 |
| 3-Bromo-3-deazaneplanocin and 3-bromo-3-deazaaristeromycin: synthesis and antiviral activity. | Bioorganic & medicinal chemistry letters 20120815 |
| Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. | Molecular cancer therapeutics 20120801 |
| 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. | International journal of cancer 20120601 |
| Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer. | Oncogene 20120412 |
| The role of histone methyltransferase EZH2 in myelodysplastic syndromes. | Expert review of hematology 20120401 |
| Derivation of new human embryonic stem cell lines reveals rapid epigenetic progression in vitro that can be prevented by chemical modification of chromatin. | Human molecular genetics 20120215 |
| Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. | Blood 20120202 |
| Loading 3-deazaneplanocin A into pegylated unilamellar liposomes by forming transient phenylboronic acid-drug complex and its pharmacokinetic features in Sprague-Dawley rats. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20120201 |
| Cloning and characterization of polyA- RNA transcripts encoded by activated B1-like retrotransposons in mouse erythroleukemia MEL cells exposed to methylation inhibitors. | BMB reports 20120201 |
| Polycomb repressor complex-2 is a novel target for mesothelioma therapy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120101 |
| The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells. | PloS one 20120101 |
| Epigenetic regulation of endothelial lineage committed genes in pro-angiogenic hematopoietic and endothelial progenitor cells. | Circulation research 20111111 |
| (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. | Carcinogenesis 20111001 |
| The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. | Blood 20110908 |
| PRAJA1 is a ubiquitin ligase for the polycomb repressive complex 2 proteins. | Biochemical and biophysical research communications 20110513 |
| S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. | Breast cancer research and treatment 20110501 |
| Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. | Haematologica 20110501 |
| Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. | Biochemical pharmacology 20110215 |
| Quantification of 3-deazaneplanocin A, a novel epigenetic anticancer agent, in rat biosamples by hydrophilic interaction liquid chromatography-tandem mass spectrometric detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110201 |
| Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells. | PloS one 20110101 |
| Polycomb target genes are silenced in multiple myeloma. | PloS one 20100101 |
| Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. | Molecular cancer therapeutics 20091201 |
| Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. | Blood 20090924 |
| DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. | Molecular cancer therapeutics 20090601 |
| BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. | Breast cancer research : BCR 20090101 |
| DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. | Cancer cell 20080601 |
| Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. | Genes & development 20070501 |
| Blockade of murine erythroleukemia cell differentiation by hypomethylating agents causes accumulation of discrete small poly(A)- RNAs hybridized to 3'-end flanking sequences of beta(major) globin gene. | Biochimica et biophysica acta 20050322 |
| John Montgomery's legacy: carbocyclic adenosine analogues as SAH hydrolase inhibitors with broad-spectrum antiviral activity. | Nucleosides, nucleotides & nucleic acids 20050101 |
| Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine. | Antiviral chemistry & chemotherapy 20040101 |
| Anti-HIV-1 activity of 3-deaza-adenosine analogs. Inhibition of S-adenosylhomocysteine hydrolase and nucleotide congeners. | European journal of biochemistry 20030901 |
| Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. | Antiviral research 20030101 |
| Identification of active antiviral compounds against a New York isolate of West Nile virus. | Antiviral research 20020701 |
| 3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice. | Antiviral research 20020701 |
| The role of the Type I interferon response in the resistance of mice to filovirus infection. | The Journal of general virology 20010601 |
| Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. | Clinical microbiology reviews 20010401 |
| Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. | Antiviral research 20000201 |
| Carboxy terminal variants of Epstein-Barr virus-encoded latent membrane protein 1 during long-term human immunodeficiency virus infection: reliable markers for individual strain identification. | The Journal of infectious diseases 19990101 |
| Carbocyclic adenosine analogues as S-adenosylhomocysteine hydrolase inhibitors and antiviral agents: recent advances. | Nucleosides & nucleotides 19980101 |
| S-adenosylhomocysteine hydrolase inhibitors interfere with the replication of human immunodeficiency virus type 1 through inhibition of the LTR transactivation. | Molecular pharmacology 19971201 |
| Anti-human immunodeficiency virus 1 (HIV-1) activities of 3-deazaadenosine analogs: increased potency against 3'-azido-3'-deoxythymidine-resistant HIV-1 strains. | Proceedings of the National Academy of Sciences of the United States of America 19950103 |
| Inhibitory activity of S-adenosylhomocysteine hydrolase inhibitors against human cytomegalovirus replication. | Antiviral research 19930701 |
| Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro. | Antiviral research 19900101 |
| Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5'-nor derivatives. | Antimicrobial agents and chemotherapy 19890801 |
| Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities. | Journal of medicinal chemistry 19890701 |
| 3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. | Biochemical and biophysical research communications 19860313 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.